Andrew Kraft to Boronic Acids
This is a "connection" page, showing publications Andrew Kraft has written about Boronic Acids.
Connection Strength
1.303
-
Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade. Cancer Biol Ther. 2011 Jul 15; 12(2):119-24.
Score: 0.384
-
Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region. Mol Cancer Ther. 2008 May; 7(5):1091-100.
Score: 0.307
-
The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther. 2005 Mar; 4(3):443-9.
Score: 0.247
-
The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene. 2003 Aug 07; 22(32):4953-63.
Score: 0.221
-
Phosphorylation of AML1/RUNX1 regulates its degradation and nuclear matrix association. Mol Cancer Res. 2005 Jul; 3(7):391-401.
Score: 0.063
-
A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer. 2005 Apr 01; 103(7):1431-8.
Score: 0.062
-
Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial. BMC Cancer. 2007 Dec 03; 7:221.
Score: 0.019